Companies › Lumos Pharma
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Metabolic and endocrine; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LUM-201 Growth hormone secretagogue | – | Phase 3 | Growth Hormone Deficiency (GHD); Growth Hormone Deficiency | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06948214 | LUM-201 | Phase 3 | Growth Hormone Deficiency (GHD) | Metabolic and endocrine | Dec 2027 |
| NCT04806854 | LUM-201 | Phase 2 | Growth Hormone Deficiency | Metabolic and endocrine | Apr 2030 |
No annotated target.
–
BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. Xintian Pharmaceutical Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Orphalan Neuvosyn Laboratories
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.